Liver-derived lipoproteins and inflammation: from pathophysiology to pharmacological targets in metabolic liver disease
Articolo
Data di Pubblicazione:
2022
Citazione:
Liver-derived lipoproteins and inflammation: from pathophysiology to pharmacological targets in metabolic liver disease / A. Baragetti. - In: METABOLISM AND TARGET ORGAN DAMAGE. - ISSN 2769-6375. - 2:(2022), pp. 9.1-9.15. [10.20517/mtod.2022.09]
Abstract:
Low density lipoproteins (LDL) reduction remains the key goal for reducing the risk of atherosclerotic
cardiovascular diseases (CVD) in people with high residual risk and metabolic complications including liver
disease. Notwithstanding, epidemiological projections support a key role of liver-derived apolipoprotein B (ApoB)
containing lipoproteins, namely very low density lipoproteins (VLDL) and their “remnants” (TG), undergoing the
activity of lipases, in eliciting atherosclerotic inflammatory sequelae of a comparable order of magnitude to that of
LDL. Disparate experimental evidence supports that triglycerides (TG), residual cholesterol content, or the large
apolipoprotein set on the surface of these lipoproteins can elicit a number of plausible immune-inflammatory
mechanisms that foster the vascular atherosclerotic process. Therapeutic options that convincingly lowered the
plasma levels of liver-derived ApoB containing lipoproteins, either by reducing the hepatic synthesis or by
improving the peripheral lipolysis of the lipid content, did not exert robust CVD risk reduction, and the effect on
inflammation was questionable. Understanding the mechanisms linking liver-derived lipoproteins with chronic
inflammation will provide pathophysiological insights for the identification of new therapeutic targets for people at
high CVD risk and with metabolic complications. In this perspective, this topic is of immediate interest for the
prevention of CVD in patients affected by non-alcoholic fatty liver disease (NAFLD) and, even more, for NAFLD
patients with diabetes, insulin resistance, or other comorbidities (metabolic-associated fatty liver disease). This
review resumes the principal physio-pathological insights regarding the metabolism of liver-derived lipoproteins
and provides an update on the current pharmacological options that can be considered for improving CVD prevention in metabolic liver diseases.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Very Low Density Lipoproteins; postprandial lipemia; inflammation; apolipoprotein B
Elenco autori:
A. Baragetti
Link alla scheda completa: